Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 311 clinical trials
Featured trial
HERV-E TCR Transduced Autologous T Cells in People With Metastatic Clear Cell Renal Cell Carcinoma

. Researchers want to see if this therapy fights kidney cancer cells. Metastatic renal cell carcinoma (RCC) is an incurable condition. Current therapy for this disease consists of the serial administration

carcinoma
clear cell renal cell carcinoma
clear cell carcinoma
metastatic cancer
renal cell cancer
  • 208 views
  • 22 Dec, 2020
  • 1 location
Featured trial
A Phase 1/1b Study of Sitravatinib in Combination with Nivolumab and Ipilimumab in Patients with Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies

Study 516-008 is an open-label Phase 1 dose escalation/Phase 1b dose expansion study evaluating the safety and tolerability, clinical activity, and PK of sitravatinib in combination with nivolumab and ipilimumab for the treatment of ccRCC and potentially other solid tumor types. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor …

carcinoma
systemic therapy
VEGFR2
ipilimumab
nivolumab
  • 57 views
  • 15 Sep, 2020
  • 1 location
Featured trial
A Phase 1b, Dose-escalation Study of Pexa-Vec (Thymidine Kinase-Deactivated Vaccinia Virus Plus GM-CSF) in Combination With REGN2810 (Anti-PD-1) in Patients With Metastatic or Unresectable Renal Cell Carcinoma (RCC)

This is a Phase 1b, open-label, multi-center, dose-escalation trial of Pexa-Vec plus REGN2810 in patients with metastatic or unresectable renal cell carcinoma (RCC). The trial consists of a

carcinoma
systemic therapy
renal function tests
cancer
renal cell cancer
  • 2 views
  • 23 Nov, 2020
  • 3 locations
Featured trial
VastBiome: The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors

The microbiome has the potential to serve as a robust biomarker of clinical response to immunotherapy. Additionally, microbial manipulation, through diet, exercise, prebiotics, probiotics, or microbially-derived metabolites, may prove to be beneficial in promoting anti-tumor immune responses. However, large prospective studies in humans with longitudinal sample collection and standardized methods …

cancer chemotherapy
programmed cell death 1 ligand 1
cancer
targeted therapy
  • 0 views
  • 28 Feb, 2022
  • 1 location
Featured trial
Procurement of Human Biospecimens for Research

Procurement of Human Biospecimens for Research

  • 80 views
  • 23 Nov, 2020
  • 1 location
Featured trial
Procurement of Human Biospecimens for Research

Procurement of Human Biospecimens for Research

  • 53 views
  • 23 Nov, 2020
  • 1 location
DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies

adenosine A2A receptor antagonist), in patients with advanced clear cell renal cell carcinoma and other malignancies with HIF stabilizing mutations.

carcinoma
everolimus
clear cell renal cell carcinoma
cancer
vegf
  • 16 views
  • 30 Jun, 2022
  • 10 locations
A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma

The purpose of this study is to evaluate MEDI5752 in combination with Lenvatinib (or Axitinib), in subjects with advanced renal cell carcinoma.

  • 28 views
  • 11 Jul, 2022
  • 12 locations